Article
Radiology, Nuclear Medicine & Medical Imaging
Christos Sachpekidis, Annette Kopp-Schneider, Leyun Pan, Dimitrios Papamichail, Uwe Haberkorn, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauss
Summary: This study aimed to investigate the prognostic role of [F-18]FDG PET/CT in predicting long-term outcomes to immunotherapy in metastatic melanoma. The results showed that PET/CT-based response to PD-1 blockade is significantly correlated with progression-free survival (PFS), highlighting its potential for early stratification of response to anti-PD-1 agents.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Medicine, General & Internal
Ken Kudura, Florentia Dimitriou, Daniela Mihic-Probst, Urs J. Muehlematter, Tim Kutzker, Lucas Basler, Robert Forster, Reinhard Dummer, Joanna Mangana, Lars Husmann, Irene A. Burger, Michael Christoph Kreissl
Summary: The use of FDG-PET/CT in metastatic melanoma patients has increased significantly due to improved survival rates. Indeterminate findings on FDG-PET/CT in these patients should be further investigated, as almost half of them are malignant with the majority being melanoma metastases. Other primary malignancies are also found in a significant proportion of cases, impacting clinical management in the majority of malignant findings.
Review
Medicine, General & Internal
Maria Mangas Losada, Leonardo Romero Robles, Alejandro Mendoza Melero, Irene Garcia Megias, Amos Villanueva Torres, Puy Garrastachu Zumaran, Xavier Boulvard Chollet, Egesta Lopci, Rafael Ramirez Lasanta, Roberto C. Delgado Bolton
Summary: Immunotherapy manipulates the immune system to target tumor cells, especially in melanoma patients. Challenges include finding evaluation criteria, identifying atypical response patterns, using PET biomarkers, and managing immunorelated adverse effects. This review focuses on the role of [F-18]FDG PET/CT in these challenges and its efficacy. Modified response criteria may be suitable for evaluating immunotherapy benefits, and [F-18]FDG PET/CT biomarkers show promise in predicting and assessing response. Immunorelated adverse effects can be early predictors of response and associated with better prognosis and benefit.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru, Benjamin Lewis Franc
Summary: The study aimed to investigate the prognostic value of F-18-FDG PET/CT parameters in melanoma patients before starting anti-PD-1 therapy. Results showed that patients with a high BLR were associated with poorer progression-free and overall survival, potentially due to systemic inflammation leading to immunosuppression.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Oncology
F. Dimitriou, S. N. Lo, A. C. Tan, L. Emmett, R. Kapoor, M. S. Carlino, G. Long, A. M. Menzies
Summary: In a retrospective analysis of 104 patients treated with PD-1 inhibitors, the majority maintained stable responses at 5 years, particularly those with CMR. PET was found to be a better predictor of progression than CT, especially in patients with residual disease on CT. Despite progression events, patients with solitary sites of progression managed locally had excellent long-term overall survival rates.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Ken Kudura, Florentia Dimitriou, Lucas Basler, Robert Forster, Daniela Mihic-Probst, Tim Kutzker, Reinhard Dummer, Joanna Mangana, Irene A. Burger, Michael C. Kreissl
Summary: For melanoma patients undergoing immune checkpoint inhibition, FDG-PET/CT can predict early treatment response. SUV peak and volume variation of metastases are strong outcome predictive biomarkers on a metastasis-level. On a patient-level, total tumor volume and semiquantitative parameters of all metastases show promise as outcome predictive biomarkers.
Article
Oncology
Christos Sachpekidis, Jessica C. Hassel, Annette Kopp-Schneider, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss
Summary: This study investigated the predictive role of quantitative, dynamic PET/CT performed early during PD-1 blockade in metastatic melanoma patients. The findings revealed that certain PET/CT parameters had an impact on progression-free survival, highlighting the potential of this method in predicting disease progression for patients under PD-1 blockade.
Article
Radiology, Nuclear Medicine & Medical Imaging
Gregor Schweighofer-Zwink, Reyhaneh Manafi-Farid, Peter Kolblinger, Lukas Hehenwarter, Sara Harsini, Christian Pirich, Mohsen Beheshti
Summary: This study evaluated the prognostic value of various metabolic parameters in 2-[F-18]FDG PET/CT scans for melanoma patients undergoing immunotherapy. The results showed that metabolic parameters in baseline and follow-up scans were predictive of 3- and 5-year overall survival rates. The 3-month follow-up scan was particularly important for prognosis assessment.
EUROPEAN JOURNAL OF RADIOLOGY
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Mathieu Spaas, Bliede Van den Broeck, David Creytens, Vibeke Kruse, Piet Ost
Summary: This case demonstrates the utility of F-18-FDG PET/CT in the early detection and monitoring of radiation myositis and highlights the importance of a multidisciplinary approach in melanoma care.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Immunology
Karim Amrane, Coline Le Meur, Philippe Thuillier, Jacques Dzuko Kamga, Pierre Alemany, Frederic Chauvelot, Clemence Niel, Alex Bellange, Ronan Abgral
Summary: This study reports a very rare case of secondarily metastatic uveal melanoma with a dramatic response to pembrolizumab along with serial pseudogression. 18F-FDG-PET, clinical status, and dNLR were used as guidance for therapeutic strategy due to an atypical pseudoprogression phenomenon.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Melvika Pereira, Anjali Prakash, Ameya D. Puranik, Nilendu Purandare, Sneha Shah, Archi Agrawal, Venkatesh Rangarajan
Summary: This case described a patient with metastatic osteosarcoma developing pancreatitis after treatment with regorafenib, highlighting the importance of recognizing rare adverse effects of tyrosine kinase inhibitors. The patient's symptoms, serum markers, and imaging findings provided the basis for diagnosis and management.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Oncology
Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, Neil J. Shah, David Swoboda, Kellie Gardner, Arash Radfar, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refaie, Suthee Rapisuwon, Michael B. Atkins
Summary: A retrospective study of 122 patients with advanced melanoma treated with anti PD-1 therapy found that discontinuation of treatment after 12 months when no active disease is observed on imaging or biopsy may have low rates of disease relapse. Biopsy of residual disease may frequently lead to a change in management.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Editorial Material
Medicine, General & Internal
Romain-David Seban, Anne Donnadieu, Gabrielle Journo, Francois-Clement Bidard, Capucine Richard, Roman Rouzier, Laurence Champion
Summary: The case report described a patient with endometrial cancer receiving dostarlimab immunotherapy showing a complete metabolic response on PET/CT and MRI, indicating the potential efficacy of this treatment for recurrent endometrial cancer.
Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Narjess Ayati, Zahra Jamshidi-Araghi, Magdalena Hoellwerth, Gregor Schweighofer-Zwink, Wolfgang Hitzl, Peter Koelblinger, Christian Pirich, Mohsen Beheshti
Summary: This study assessed tumor response in patients with metastatic melanoma treated with ICIs using three modified response criteria. Results showed that PERCIMT provided a more reliable assessment of disease control rate and overall patient survival.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ayaz Aghayev, Andreas A. Giannopoulos, Jessica Gronsbell, Elizabeth George, Tianxi Cai, Michael L. Steigner, Dimitrios Mitsouras, Frank J. Rybicki
AMERICAN JOURNAL OF ROENTGENOLOGY
(2018)
Editorial Material
Cardiac & Cardiovascular Systems
Sumit Gupta, Yin Ge, Maaz A. Ghouri, Ron Blankstein, Michael L. Steigner, Ayaz Aghayev
CIRCULATION-CARDIOVASCULAR IMAGING
(2018)
Article
Radiology, Nuclear Medicine & Medical Imaging
Richard Thomas, Ayaz Aghayev, Michael L. Steigner
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY
(2018)
Editorial Material
Cardiac & Cardiovascular Systems
Sarah Cuddy, Barbara J. McNeil, Ayaz Aghayev, Sharmila Dorbala
JOURNAL OF NUCLEAR CARDIOLOGY
(2018)
Meeting Abstract
Cardiac & Cardiovascular Systems
Christoph Grani, Christian Eichhom, Loic Biere, Kyoichi Kaneko, Vikram Agarwal, Venkatesh Murthy, Ayaz Aghayev, Michael Steigner, Ron Blankstein, Michael Jerosch-Herold, Raymond Kwong
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2018)
Meeting Abstract
Cardiac & Cardiovascular Systems
Christoph Grani, Loic Biere, Christian Eichhorn, Kyoichi Kaneko, Vikram Agarwal, Ayaz Aghayev, Michael Steigner, Ron Blankstein, Michael Jerosch-Herold, Raymond Kwong
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2018)
Meeting Abstract
Cardiac & Cardiovascular Systems
Brittany Weber, Yin Ge, Ayaz Aghayev, Michael Steigner, Elazer Edelman
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2018)
Article
Cardiac & Cardiovascular Systems
Negareh Mousavi, Michael K. Cheezum, Ayaz Aghayev, Robert Padera, Tomas Vita, Michael Steigner, Edward Hulten, Marcio Sommer Bittencourt, Sharmila Dorbala, Marcelo F. Di Carli, Raymond Y. Kwong, Ruth Dunne, Ron Blankstein
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2019)
Article
Cardiac & Cardiovascular Systems
Christoph Graeni, Loic Biere, Christian Eichhorn, Kyoichi Kaneko, Vikram Agarwal, Ayaz Aghayev, Michael Steigner, Ron Blankstein, Michael Jerosch-Herold, Raymond Y. Kwong
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
(2019)
Editorial Material
Peripheral Vascular Disease
Caroline Galliano, Sumit Gupta, Michael L. Steigner, Ayaz Aghayev
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Ayaz Aghayev, Mandeep R. Mehra
Editorial Material
Cardiac & Cardiovascular Systems
Faisal Jamal, Mohammad Saud Khan, Jing Yang, Michael L. Steigner, Abhishek Keraliya, Ayaz Aghayev
CIRCULATION-CARDIOVASCULAR IMAGING
(2021)
Article
Cardiac & Cardiovascular Systems
Ayako Seno, Panagiotis Antiochos, Helena Lichtenfeld, Eva Rickers, Iqra Qamar, Yin Ge, Ron Blankstein, Michael Steigner, Ayaz Aghayev, Michael Jerosch-Herold, Raymond Y. Kwong
Summary: Recent research has found that the assessment of extracellular volume fraction (ECV) and global longitudinal strain (GLS) by cardiac magnetic resonance can provide valuable prognostic information for predicting all-cause death or heart failure hospitalizations in patients suspected of heart failure. This incremental prognostic value of ECV and GLS goes beyond traditional markers such as left ventricular ejection fraction (LVEF) and late gadolinium enhancement (LGE). Additionally, the joint assessment of GLS and ECV has been shown to significantly improve model discrimination and risk reclassification for adverse outcomes in this patient population.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Azadehsadat Esfahani, Ayaz Aghayev
Article
Cardiac & Cardiovascular Systems
Ayaz Aghayev, Camden P. Bay, Sara Tedeschi, Paul A. Monach, Umberto Campia, Marie Gerhard-Herman, Michael L. Steigner, Richard N. Mitchell, William P. Docken, Marcelo DiCarli
Summary: The study compared the imaging features and clinical outcomes of patients with carotid artery inflammation (CIA) and giant cell arteritis/aortitis (GCA), showing that CIA patients mainly presented with cardiovascular symptoms without systemic inflammatory symptoms, and there was no significant difference in clinical outcomes between the two groups.
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
(2021)
